<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04618939</url>
  </required_header>
  <id_info>
    <org_study_id>BR-TD-1001-CH-301</org_study_id>
    <nct_id>NCT04618939</nct_id>
  </id_info>
  <brief_title>To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children</brief_title>
  <official_title>Double Blind, Randomized Phase III Study to Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Biopharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Biopharma Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate immunogenicity by measuring the seroprotection rate&#xD;
      against diphtheria and tetanus at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary objective:&#xD;
&#xD;
      To evaluate immunogenicity by measuring the seroprotection rate against diphtheria and&#xD;
      tetanus at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.&#xD;
&#xD;
      Secondary objectives:&#xD;
&#xD;
        -  To evaluate immunogenicity by measuring the geometric mean titer (of diphtheria and&#xD;
           tetanus antitoxins at 28 days after vaccination with BR-TD-1001 and Td-pur-inj.&#xD;
&#xD;
        -  To evaluate a boosting response by comparing before and after the administration through&#xD;
           measurement of diphtheria and tetanus antitoxin titers at 28 days after vaccination with&#xD;
           BR-TD-1001 and Td-pur-inj.&#xD;
&#xD;
        -  To evaluate safety by observing solicited local and systemic adverse events that have&#xD;
           occurred for 7 days after vaccination with BR-TD-1001 and Td-pur-inj.&#xD;
&#xD;
        -  To evaluate safety by observing unsolicited adverse events that have occurred for 28&#xD;
           days after vaccination with BR-TD-1001 and Td-pur-inj.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 20, 2016</start_date>
  <completion_date type="Actual">April 28, 2017</completion_date>
  <primary_completion_date type="Actual">April 28, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The seroprotection rate of anti-diphtheria toxoid (DT) and anti-tetanus toxoid (TT) at 28 days after vaccination with the investigational products</measure>
    <time_frame>28 days after vaccination</time_frame>
    <description>Seroprotection was defined as anti-DT and anti-TT antibody concentrations ≥ 0.1 IU/mL (ELISA)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The geometric mean titer (GMT) of anti-DT and anti-TT at 28 days after vaccination with the investigational products</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The boosting response for antitoxins of diphtheria and tetanus at 28 days after vaccination with the investigational product</measure>
    <time_frame>28 days after vaccination</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Diphtheria</condition>
  <condition>Tetanus</condition>
  <arm_group>
    <arm_group_label>BR-TD-1001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized subjects were assigned to receive a single dose of BR-TD-1001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Td-pur inj</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Randomized subjects were assigned to receive a single dose of Td-pur inj</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BR-TD-1001</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>BR-TD-1001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Td-pur inj</intervention_name>
    <description>0.5 mL, IM</description>
    <arm_group_label>Td-pur inj</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy boys and girls aged 10 to 12 years&#xD;
&#xD;
          2. Those who received primary immunization (5 doses of diphtheria and tetanus vaccination&#xD;
             until the age of 6)&#xD;
&#xD;
          3. Voluntary written consent of the subject and the legally acceptable&#xD;
             representative(LAR) to participate in this clinical study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. 2 weeks have not passed since recovery from an acute disease&#xD;
&#xD;
          2. Temporary thrombocytopenia or neurological complications due to diphtheria or tetanus&#xD;
             vaccination&#xD;
&#xD;
          3. History of a severe allergy to any component of the investigational product&#xD;
&#xD;
          4. History of a severe adverse event due to administration of diphtheria, tetanus, or&#xD;
             diphtheria tetanus combined vaccine&#xD;
&#xD;
          5. Administration of tetanus, diphtheria, or diphtheria tetanus combined vaccine within 5&#xD;
             years&#xD;
&#xD;
          6. Unable to verify diphtheria and tetanus vaccination completed until the age of 6&#xD;
&#xD;
          7. History of infection with diphtheria or tetanus (if clinically, serologically or&#xD;
             microbiologically confirmed)&#xD;
&#xD;
          8. Current chronic disease that impedes implementation or completion of the clinical&#xD;
             study&#xD;
&#xD;
          9. Scheduled surgery during the study period&#xD;
&#xD;
         10. Acute fever with a tympanic temperature exceeding 38.0ºC within 72 hours before&#xD;
             administration of the investigational vaccine&#xD;
&#xD;
         11. Administration of other vaccines within 28 days before screening&#xD;
&#xD;
         12. Use of immunosuppressants or immune modifying drugs within 3 months before screening&#xD;
&#xD;
         13. Those who have received immunoglobulin therapies or blood derived products within 3&#xD;
             months before screening, or are expected to receive them during the study period&#xD;
&#xD;
         14. Use of antipyretics/analgesics/nonsteroidal anti inflammatory drugs within 4 hours&#xD;
             before administration of the investigational vaccine&#xD;
&#xD;
         15. Participation in other clinical studies within 28 days before screening&#xD;
&#xD;
         16. Those who were determined by the investigator to be ineligible for other reasons&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jong Hyun Kim</last_name>
    <role>Study Chair</role>
    <affiliation>Saint Vincent's Hospital, Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Changwon Fatima Hospital</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Daejeon St. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Incheon St. Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Eulji General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanil General Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea Cancer Center Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea St. Paul's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Severance Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 2, 2020</study_first_submitted>
  <study_first_submitted_qc>November 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2020</study_first_posted>
  <last_update_submitted>November 18, 2020</last_update_submitted>
  <last_update_submitted_qc>November 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diphtheria</keyword>
  <keyword>Tetanus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetanus</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

